

**A randomised Phase III trial of Dexamethasone and Aspirin (DA) versus Dexamethasone, Diethylstilbestrol and Aspirin (DAS) in locally advanced or metastatic cancer of the prostate – immediate versus deferred diethylstilbestrol**

J Shamash<sup>2</sup>, T Powles<sup>2</sup>, P Wilson<sup>2</sup>, S McFaul<sup>1</sup>, W Ansell<sup>2</sup>, A Davies<sup>1</sup>, E Walsh<sup>2</sup>, T Oliver<sup>2</sup>

<sup>1</sup>St Bartholomew's Hospital, London, United Kingdom; <sup>2</sup>Queen Mary University of London, London, United Kingdom

Following the failure of Androgen Deprivation in the management of advanced prostate cancer, several options are available. These include further endocrine therapy (corticosteroids & estrogens) as well as systemic chemotherapies. Both corticosteroids and estrogens lead to improvements in symptoms with falls in PSA. However the optimal sequencing of these drugs remains unclear.

The primary objective of this study is to compare PSA response in patients randomised to:

1. Dexamethasone (2mg/day) & Aspirin (75mg/day) with the additional of Diethylstilbestrol (1mg/day) or
2. to the immediate use of Dexamethasone, Aspirin & Diethylstilbestrol.

The secondary objectives are to compare overall response, quality of life (EORTC QLQ-C30 & PR25) progression free and overall survival, and to assess PSA response subsequent to the addition of diethylstilbestrol in Group 1.

This is a multi-centre, randomised, controlled study with stratification according to performance status, PSA response to previous therapy and positive or negative bone scan. To date 125 patients have been randomised from 3 centres with another 9 approved for recruitment. An interim analysis is being performed and results will be presented at this meeting.